We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
By Stephen Nakrosis
Gilead Sciences, Inc. on Friday said the Food and Drug Administration expanded the Emergency Use Authorization for Veklury, permitting use of the investigational antiviral Veklury, or remdesivir, to treat all hospitalized patients with Covid-19.
Previously, the EUA allowed for the use of Veklury to treat patients hospitalized with severe Covid-19, the company said.
Merdad Parsey, the company's chief medical officer, said "As we learn more about Covid-19 and we further establish the efficacy and safety profile of Veklury, we see benefit to making the drug available to patients at earlier stages of the disease. Today's action by the FDA enables physicians to consider a broader range of eligible patients to potentially receive Veklury."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 28, 2020 17:27 ET (21:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions